^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Hormone receptor inhibition as a strategy for radiosensitization of breast cancer

Published date:
05/15/2020
Excerpt:
AR inhibition with enzalutamide, apalutamide, and darolutamide showed limited single agent growth inhibition efficacy in AR+ TNBC and AR+, ER+ breast cancer cell lines (IC50 > 10 μM).